Malignancy-related events over time for all-bari-RA analysis set (IR).

Slides:

Advertisements

Similar presentations

Lenalidomide and Dexamethasone (LEN plus DEX) Treatment in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (pts) and Risk of Second Primary Malignancies.

Advertisements

Time to Distant Metastases (ITT) Cumulative incidence of distant metastases (ITT) Adapted from Jones et al. SABCS 2008, abstract /477169/465253/454771/ /4146.

© Cancer Research UK 2008 Registered charity number Incidence – UK February 2008.

1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2014.

Module 1 Prof. Hassan Bassiouny, MD Prof. Of Rheumatology, Al-Azhar University Cairo, Egypt RHUHQ12PM028 Date of preparation: January 2012 Targeting the.

The Risk of Cancer Following Total Hip or Knee Arthroplasty by Ravi Tharani, Frederick J. Dorey, and Thomas P. Schmalzried J Bone Joint Surg Am Volume.

Summary of TB cases across indications and trial periods

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Nat. Rev. Rheumatol. doi: /nrrheum

A Critical Evaluation of Clinical Research Study Designs

Pre (a) and post (b) contrast agent short-axis images of the third metatarsophalangeal (MTP) joint demonstrating intact capsule and plantar plate (arrows).

Nat. Rev. Rheumatol. doi: /nrrheum

Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data Bruce Strober, MD,

Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.

Patient disposition during open-label longterm exposure period.

Benefit-risk balance. Benefit-risk balance. Predicted probabilities of developing serious infection versus predicted probabilities of achieving Boolean-based.

Percentage of patients achieving minimal disease activity (MDA): A

ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,

Clinical relevance of thrombocytosis in primary care: a prospective cohort study of cancer incidence using English electronic medical records and cancer.

Transmission map of P. jirovecii among outpatients with RA

Nat. Rev. Rheumatol. doi: /nrrheum

Work arrangements, productivity, and self-confidence at work as affected by RA. a For example: Stopped working altogether, moved from full-time to part-time.

RA also increases the risk for work disability and therefore impacts livelihood. The percentage of RA patients who quit working after only.

Percentages of (A) ACR 20, 50, and 70 responders, and (B) patients with DAS28-CRP ≤ 3.2 or < 2.6 during 5 years. Percentages of (A) ACR 20, 50, and 70.

Updated 2016 PsA Core Domain Set.

Nat. Rev. Rheumatol. doi: /nrrheum

Kaplan–Meier curve for the time until the development of lung cancer in patients with idiopathic pulmonary fibrosis. Kaplan–Meier curve for the time until.

Volume 151, Issue 1, Pages e4 (July 2016)

Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.

Gastrointestinal Effects of NSAIDs and Coxibs

Changes in the proportion (95% CI) of patients with (A) fatal events, (B) serious infections, (C) malignancy, (D) GI perforation, and (E) serious cardiac.

Risk of Nonmelanoma Skin Cancer in Patients With Inflammatory Bowel Disease Who Use Thiopurines Is Not Increased Fiona D.M. van Schaik, Martijn G.H.

Figure 8 HRQOL in individuals with RA

Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with significant synovitis defined by GS≥ grade.

PPD status of CZP-treated patients with RA in the pooled RA safety database (N=4049) at baseline and TB incidence by INH treatment. †One patient who developed.

Mean change from baseline CDAI in abatacept and TNFi initiators with a typical patient profile. Mean change from baseline CDAI in abatacept and TNFi initiators.

Cumulative incidence of tuberculosis (TB) in certolizumab pegol (CZP)-treated patients with rheumatoid arthritis (RA) in the pooled RA safety database.

Volume 151, Issue 1, Pages e4 (July 2016)

Nat. Rev. Cardiol. doi: /nrcardio

Calprotectin levels in children with enthesis-related arthritis (ERA), arthritis controls (oligoarticular and polyarticular juvenile idiopathic arthritis),

Tumor Recurrence 5 Years after Treatment of Cutaneous Basal Cell Carcinoma and Squamous Cell Carcinoma Mary-Margaret Chren, Eleni Linos, Jeanette S.

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

Mean differences with 95% CI between the Internal Family Systems (IFS) intervention group and the education group in study outcomes at baseline and 3,

by Paul Baughan, Jennifer Keatings, and Bill O'Neill

Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.

Patient disposition, weeks 24–128.

CAPP2: Time to first colorectal cancer in those randomized to aspirin compared with those randomized to the aspirin placebo. CAPP2: Time to first colorectal.

A. A. Change from baseline in Genant-modified Sharp total score. B. Erosion score. C. Joint-space narrowing score in patients originally randomized to.

The association between alcohol consumption and the severity of MRI-detected inflammation in hand and foot joints of (A) patients with RA and (B) asymptomatic.

Patient-reported adherence towards different IMID treatments in RA (A), PsA (B) or AS (C). Patient-reported adherence towards different IMID treatments.

Clinical response in patients with early and established RA at month 24. *p

Clinical expertise of GPs and rheumatologists in differentiating patients with arthralgia. Clinical expertise of GPs and rheumatologists in differentiating.

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

A. A. Percentages of patients with active dactylitis in ≥ 4 digits (fingers or toes) at baseline and Week 12. *p < versus baseline. Data are observed.

Satisfaction with control of RA

Kevan G. Lewis, Martin A. Weinstock

SIR data for all CZP-treated patients (RCT+OLE) for each malignancy type, standardised to the general population by age and gender (GLOBOCAN and SEER).

(A) Mean (95% CI) change and (B) mean percentage (SE) change in enthesitis scores (Leeds Enthesitis Index, SPARCC Enthesitis Index, and MASES) from baseline.

Pooled estimate of relative risk and 95% CIs of colorectal cancer associated with metformin therapy based on four studies comprising 107,961 diabetic patients.

All SAE* over time in 5 years.

Fluorescein angiogram of the right eye shows patchy staining of the peripheral retinal veins in the right eye, and nonperfusion of the peripheral retina.

Incidence rates of hospitalised infection per 100 person-years, standardised for age and sex, among patients with RA from five RA registries and one RA.

The mTSS individual-patient change from baseline to Week 52 cumulative probability plot (observed data). The mTSS individual-patient change from baseline.

ACR20, ACR20 and ACR70 response rates (proportions of patients meeting ACR 20, 50% or 70% improvement criteria) in patients with rheumatoid arthritis randomised.

Multivariate Cox proportional hazards model of time to first serious infectious events. Multivariate Cox proportional hazards model of time to first serious.

Changes in non-classical (CD11b+CD14+CD163−CD16+) and classical (CD11b+CD14+CD163+CD16−) monocytes over time in patients with rheumatoid arthritis (RA)

Incidence rates over time of SAEs, malignancies and TB pre-2007 and post-2007 for RCT PBO and CZP-treated patients (all doses) in the combined RCT and.

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Presentation transcript:

Malignancy-related events over time for all-bari-RA analysis set (IR). Malignancy-related events over time for all-bari-RA analysis set (IR). A. Cumulative incidence rate of malignancy (excluding NMSC) by time period for all-bari-RA patients (IR per 100 PY; 95% CI). B. Cumulative incidence rate of NMSC by time period of report for all-bari-RA patients (IR per 100 PY; 95% CI). RA: rheumatoid arthritis; IR: incidence rate; NMSC: nonmelanoma skin cancer; PY: patient-years. Josef S. Smolen et al. J Rheumatol 2019;46:7-18 ©2019 by The Journal of Rheumatology